Study of Immune Cells in Obese Patients With Type 2 Diabetes Mellitus Treated With Liraglutide
NCT ID: NCT02201550
Last Updated: 2014-07-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
9 participants
OBSERVATIONAL
2013-02-28
2014-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The hypotheses are:
* Glucagon-like peptide-1 has an immunological effect observed by studying immune cells in the blood
* Treatment with glucagon-like peptide-1 increases the number of immune cells in the blood
* Treatment with glucagon-like peptide-1 leads to a more anti-inflammatory cytokine profile in the blood
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of Physical Training and GLP-1 Receptor Agonist Liraglutide Treatment in Patients With Type 2 Diabetes
NCT01455441
The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes
NCT01795248
The Lira Pump Trial
NCT02351232
Liraglutide in Newly Onset Type 1 Diabetes.
NCT01879917
The Effect of Liraglutide on Pancreatic Hormones and Its Size
NCT03520062
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Liraglutide
Patients with type 2 diabetes undertaking treatment with liraglutide
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI \> 27 kg/m2
* Planed start of treatment with liraglutide
* Age \> 18 years
Exclusion Criteria
* Immunomodulating treatment (i.e nonsteroidal antiinflammatory drugs, glucocorticoids)
* Smoking
* Alcohol consumption \> 14 beverages/week
* Former bariatric surgery
18 Years
80 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zealand Pharma
INDUSTRY
Hvidovre University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Carsten Dirksen
MD, PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Carsten Dirksen, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Hvidovre University Hospital
Sten Madsbad, MD, DMSc
Role: PRINCIPAL_INVESTIGATOR
Hvidovre University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hvidovre University Hospital
Hvidovre, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-2-2012-148-KLB
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.